Medicare data breach exposes 100,000 Americans' info
The Centers for Medicare & Medicaid Services (CMS) sent letters this week to those affected, confirming that hackers accessed sensitive data linked to Medicare.gov accounts.
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my CYBERGUY.COM/NEWSLETTER
Over 8M Patient Records Leaked In Healthcare Data Breach
The breach traces back to suspicious activity starting in late 2023. According to CMS, cybercriminals used stolen personal data from external sources to fraudulently create Medicare.gov accounts.
That information included:
Read On The Fox News App
Full names
Dates of birth
ZIP codes
Medicare Beneficiary Identifiers (MBIs)
Medicare coverage details
CMS began receiving alerts in May 2025 when people reported receiving account confirmation letters for accounts they had not created. This triggered an internal investigation. Hackers not only created unauthorized accounts but, in some cases, accessed additional sensitive data such as:
Home addresses
Provider and diagnosis codes
Services received
Plan premium details
CMS has deactivated all affected accounts and is mailing new Medicare cards to the estimated 103,000 individuals affected. The agency says no confirmed identity theft cases have been reported yet. CMS stressed the action is being taken out of "an abundance of caution," but the breach raises questions about federal cybersecurity safeguards.
If you're one of the people affected by the Medicare data breach:
Watch your mailbox for a replacement Medicare card
Monitor your Medicare.gov account for suspicious activity
Report unauthorized services or charges immediately
CMS is still investigating how the attackers obtained such accurate personal data and whether more individuals may be at risk.
What Is Artificial Intelligence (Ai)?
So far, CMS has not identified the attackers. However, the use of valid personal information suggests that the hackers may have obtained data from prior breaches or leaks on other platforms. This breach reveals a troubling vulnerability in the federal healthcare system, where hackers can exploit existing data to create legitimate-looking accounts and access deeply personal medical information.
Here are five important steps you can take right now to protect your Medicare information and reduce your risk of identity theft after the breach.
Regularly check your Medicare and healthcare accounts for changes you did not make. Be cautious of unfamiliar services, charges or communications from providers you don't recognize.
In light of the Medicare data breach, where bad actors used valid personal details to create fake accounts, enrolling in a trusted identity theft protection service can offer an extra layer of defense. These services monitor your Social Security number, email, phone number and other sensitive data to alert you if it's being sold on the dark web or used to open fraudulent accounts.
Many top-rated services also help you freeze your credit and bank accounts and offer expert support if your identity is compromised. My top pick includes up to $1 million in identity theft insurance to cover stolen funds and legal fees, plus access to a U.S.-based fraud resolution team that helps you recover faster.
See my tips and best picks on how to protect yourself from identity theft at Cyberguy.com/IdentityTheft
Never share your Medicare number or card details with anyone over the phone or email, unless you initiated the contact and trust the source. Treat it like a credit card.
If you believe your information is being misused, remove it from the internet. A personal data removal service can help you remove all this personal information from the internet. It has a very clean interface and will scan 195 websites for your information and remove it and keep it removed.
Check out my top picks for data removal services and get a free scan to find out if your personal information is already out on the web by visiting Cyberguy.com/DeleteGet a free scan to find out if your personal information is already out on the web: Cyberguy.com/FreeScan
If you notice suspicious activity, report it directly by calling 1-800-MEDICARE (1-800-633-4227) to report Medicare fraud. Also, file a report at IdentityTheft.gov to create a recovery plan with the Federal Trade Commission (FTC). This not only helps you recover faster but also contributes to broader investigations that protect others.
This Medicare breach may not have resulted in confirmed cases of identity theft so far, but that does not mean the situation should be taken lightly or dismissed as low risk. It took malicious actors less than two years to create over 100,000 fake Medicare accounts using valid personal information, which suggests a significant weakness in how sensitive data is being protected and monitored at the federal level.
Do you think healthcare organizations are doing enough to protect your data? Let us know by writing us at Cyberguy.com/Contact
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide — free when you join my CYBERGUY.COM/NEWSLETTER
Copyright 2025 CyberGuy.com. All rights reserved.Original article source: Medicare data breach exposes 100,000 Americans' info
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
GSK seeks FDA nod for expanded use of RSV vaccine in adults
(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age of 50 at a higher risk of the disease. If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults. GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59. While it had a lead in approvals initially, it has since lagged behind rivals and sales have fallen sharply. The FDA is expected to make a decision on the expanded use of Arexvy in the first half of 2026, GSK said. European regulators are also expected to rule on a similar application by then. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report
DaVita Inc. (NYSE:DVA) is one of the . On June 18, DaVita Inc. (NYSE:DVA) released its Community Care report, highlighting its long-standing commitment to corporate citizenship and development towards ESG goals for 2025. DaVita Inc. posted its major developments in 2024. In 2020, the company announced broadened ESG goals and has since reported progress against its five strategic focus areas, including Patient Care, Team Engagement, Environmental Stewardship, Healthy Communities, and Leading with Integrity and Accountability. The company's 100% global operations are on track to be matched by renewable energy purchases by 2025. Moreover, over 8,200 DaVita patients received a kidney transplant in 2024, the company's highest number of annual transplants to date. Chinnapong/ 'This year, we're reflecting on 25 years of patient care and progress made toward improving the health and vibrancy of the communities and people we serve. Looking ahead to the next 25 years, I'm excited about how we're positioned to build on these recent community health achievements to enhance the care experience for people around the world,' said Javier Rodriguez, chief executive officer for DaVita. DaVita Inc. (NYSE:DVA) is a healthcare provider focused on transforming care delivery to enhance the quality of life for patients worldwide. While we acknowledge the potential of DVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
24 minutes ago
- Medscape
Can This Pacemaker Overcome Stubborn Hypertension?
When medications for hypertension fail, or patients cannot adhere to the drugs, physicians may soon find themselves considering a new option for treating hypertension. Atrioventricular interval modulation (AVIM) therapy, a pacing algorithm incorporated into dual-chamber pacemakers, is being tested in patients with uncontrolled hypertension and a need for a pacemaker. Ongoing research could lead to a widened indication in patients who have uncontrolled blood pressure but do not need cardiac pacing, according to the developers of the technology. In April, the US FDA granted a Breakthrough Device Designation to Orchestra BioMed for its AVIM device, called BackBeat. According to the company, more than 7.7 million Americans meet the agency's criteria for this designation, having uncontrolled hypertension, preserved left ventricular systolic function, and a 10-year risk for atherosclerotic cardiovascular disease. David Hochman, the CEO of Orchestra BioMed, the company that created AVIM therapy, said a benefit of the technology is that it doesn't require patient adherence to medication. 'With hypertension, patients don't really necessarily feel symptoms, but they need to take medication to reduce the risk of high blood pressure, and they do feel side effects from the medicine.' Orchestra BioMed is collaborating with Medtronic on the BACKBEAT study, a randomized, double-blinded trial aiming to enroll approximately 500 patients. The MODERATO II study, on which the FDA designation was based, found patients who used the device experienced an 11.1 mm Hg ( P < .001) reduction in mean 24-hour ambulatory systolic blood pressure at 6 months, a 8.1 mm Hg greater than those managed only with antihypertensive medications. Older patients with isolated systolic hypertension are particularly challenging to manage. They 'are at higher risk of heart failure because of higher pulse pressure against a stiffer ventricle and stiffer blood vessels,' and they also are more challenging to treat,' Hochman said. 'It's a population with more unmet need and less dedicated research,' he added. Christopher DeSimone, MD, a cardiologist and electrophysiologist at Mayo Clinic in Rochester, Minnesota, said a nonpharmacologic option for uncontrolled hypertension is appealing because 'patients may have issues with compliance issues, polypharmacy and drug-drug interactions and face rising drug costs and fixed incomes.' However, he said he would like to see data showing this benefit is sustained in longer follow-up of 6-12 months. The 11 mg Hg reduction in systolic blood pressure seen in the MODERATO II trial is 'significant, and would play a big role for a lot of our patients.' A 2016 meta-analysis found every 10 mm Hg reduction in systolic blood pressure reduced the risk for major cardiovascular disease events by 20% and led to a 13% reduction in all-cause mortality. In those with pacemakers already, DeSimone said, 'the added risk of running the algorithm is essentially nothing. The patient would only stand to benefit and if not — the algorithm can be turned off.' But the implantation of a new pacing device for treating hypertension alone, he added, 'there are risks associated with the procedure, as well as infection risks given these reside in the bloodstream and can serve as a nidus for infection.' James Brian Byrd, MD, assistant professor at the University of Michigan, Ann Arbor, Michigan, and a cardiologist who researches and treats hypertension, said reducing blood pressure is 'really, really important from the perspective of public health and avoiding strokes and early deaths from heart attacks.' But he questioned whether the financial incentives of implanting a device could outweigh the incentives of adding on inexpensive medications. 'We have really well established and effective treatments that are inexpensive, that aren't used enough, and don't have champions necessarily for them,' Byrd said, referencing later-line hypertension therapies like spironolactone, amiloride, guanfacine, and eplerenone. Spironolactone, for example, is a generic drug that does not receive industry promotion, and while it can be effective in treating isolated systolic hypertension in particular, use of the m edication is associated with hyperkalemia. He worried that physicians could be financially incentivized to implant a device that does not require long-term follow-up 'as opposed to giving people medication where you have to check periodically to see whether their potassium is too high.' DeSimone agreed hypertension therapy falls short in many patients. 'It is quite difficult for the patient's family doctor to add on yet another therapy that takes time and resources to monitor in a situation that is already overwhelmed,' he said. As a result, the overwhelming majority of hypertension patients 'are not optimized, so they're not taking all of the therapies they could take or they've not been prescribed the right doses.' Hochman said that concerns that pacemakers would be overused for blood pressure are premature. Orchestra Med would need to 'produce very compelling data that satisfies regulators and ultimately satisfies the clinical community' before the pacemakers could be used to treat blood pressure alone, he explained. He added that pacemakers have become safer, with the advent of conduction system pacing. Pacemakers are also becoming easier to implant with the move toward leadless devices which are implanted fully in the heart and have a small footprint. DeSimone said the two other approved medical devices to treat blood pressure, baroreflex activation therapy and renal denervation, have had limited effectiveness and uptake. With AVIM technology 'by altering the physiology of the heart and the autonomic nervous system together, this device would fill a need that is currently lacking.' Hochman is the CEO of Orchestra BioMed, the company that created the AVIM pacemaker technology. Byrd has served on advisory boards for companies developing medications for hypertension. DeSimone reported having no relevant financial conflicts of interest.
